A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis (BROADEN2)
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study With an Open-label Period Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
Sponsor: Kymera Therapeutics, Inc.
Listed as NCT07217015, this observational or N/A phase trial focuses on Atopic Dermatitis and remains actively recruiting participants. Sponsored by Kymera Therapeutics, Inc., it has been updated 5 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
Apr 28, 2026 — Present [daily]
Recruiting
Phase: PHASE2 → None
-
Mar 2026 — Apr 2026 [monthly]
Recruiting PHASE2
-
Feb 2026 — Mar 2026 [monthly]
Recruiting PHASE2
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE2
-
Nov 2025 — Jan 2026 [monthly]
Recruiting PHASE2
First recorded
Eligibility Summary
This phase 2b study is designed to evaluate the safety and efficacy of KT-621 in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD), a common form of eczema. The main goals of this study are to learn how effective KT-621 is at reducing the severity and extent of AD, the safety and tolerability of KT-621, how KT-621 behaves in the body, and how the body responds to KT-621. This is a 16-week double-blind, placebo-controlled study with a 52-week open-label period.
Contact Information
- Kymera Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ann Arbor, United States , Ansan-si, South Korea , Augsburg, Germany , Bad Bentheim, Germany , Berlin, Germany , Birmingham, United States , Brisbane, Australia , Calgary, Canada , Cheonan, South Korea , Chorzów, Poland and 51 more locations